Navigation Links
Mast Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3
Date:11/26/2013

any's web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to the Company's development plans for MST-188 in acute limb ischemia, including its planned phase 2 clinical study.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future nonclinical and clinical studies of MST-188 and the risk that MST-188 may not demonstrate adequate safety, efficacy or tolerability in one or more such studies; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of the planned phase 2 clinical study of MST-188 in acute limb ischemia; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not su
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Northwest Biotherapeutics Completes Public Offering Of Common Stock And Warrants; Underwriter Exercises Full Over-Allotment
2. NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113
3. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
4. Central Nervous System (CNS) Therapeutics - Global Strategic Business Report 2013-2018
5. Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
6. Inhibikase Therapeutics, Inc. Elects Anthony Zook To The Board Of Directors
7. Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
8. Lightlake Therapeutics to Present at 6th Annual LD MICRO Conference
9. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
10. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
11. Prostate Cancer Therapeutics Market Worth $8.0 billion by 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , August 28, 2014 ... Market Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, ... Growth, Trends and Forecast, 2014 - 2020" the global ... billion in 2013 and is expected to grow at ... reach an estimated value of USD 5.3 billion in ...
(Date:8/28/2014)... 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... FDA clearance for and commercializing its CE Marked ... in identifying children, adolescent, and young adult patients in ... appendicitis, today announced it will present at three upcoming ... Annual Global Investment Conference being held in ...
(Date:8/28/2014)... 2014 Telik, Inc. (OTCQB: TELK), a ... with MabVax Therapeutics, Inc. on July 8, 2014, ... to the development of its lead antibody program ... the Company,s internally developed antibody discovery platform.  These ... antibody based therapeutic and diagnostic products based on ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
... traits contribute to risk, of skin cancer; findings will ... May 18 In two papers published,today, deCODE scientists ... the company,s recent findings in the genetics of pigmentation,traits ... of these,common variants also confer risk of two types ...
... Annual Meeting Will Further Demonstrate, the Strength ... CAMBRIDGE, Mass., May 16 Millennium Pharmaceuticals,The Takeda Oncology ... are scheduled to be featured at the 2008 American ... May 30 -,June 3, 2008. The data will highlight ...
Cached Medicine Technology:deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 2deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 3deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
(Date:8/28/2014)... August 28, 2014 Save On ... tech accelerator program in Tampa. Healthbox Florida has ... healthcare companies grow and achieve their goals. , ... 16th, at their launch event at the Mahaffey Theater ... , Co-founder Matt Schneider commented on the Save On ...
(Date:8/28/2014)... Commercial growers all over the continent are waitlisted to ... lights, which perform on par with 1000w HPS at 65% ... needs no cooling equipment and does not overheat the space, ... in that they never need bulbs changed, the internal ROI ... , For many indoor growers, cooler room temperatures also has ...
(Date:8/28/2014)... candidate Ebola vaccine could be given to healthy volunteers ... as September, as part of an series of safety ... that has killed more than 1,400 people in the ... this candidate vaccine, being co-developed by the US National ... accelerated with funding from an international consortium in response ...
(Date:8/28/2014)... repairing nerves with adhesives, most researchers place glue directly ... fix the nerve ends well and allows glue to ... cylindrical. However, it is difficult to insert the nerve ... and there is frictional resistance. Xiangdang Liang and co-workers ... special conduit for the adhesive technique and defined the ...
(Date:8/28/2014)... (Aug. 28, 2014) A subset of patients with ... treated with irinotecan-based therapy, according to a new study ... official journal of the American Gastroenterological Association. , When ... leucovorin adjuvant irinotecan therapy improved overall survival rates ... CIMP is seen in about 10 to 20 percent ...
Breaking Medicine News(10 mins):Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Drug shows promise for subset of stage III colon cancer patients 2
... ... Gamble Company (NYSE: PG ) today announced ... chief executive officer of WellPoint, Inc. (NYSE: ... appointment is effective immediately. , (Photo: ...
... summer camp is highly anticipated by over 11 million children ... camp can be a source of anxiety for parents. Findings ... Injury Prevention should ease their concerns however. ... first to examine the epidemiology of injury rates in a ...
... New imaging techniques could lead to better diagnoses, experts say ... twists and turns as it beats, and a German study ... women, and young and old. , In the study, published ... Imaging , researchers at University Hospital Freiburg describe the different ...
... urging against use of Lovenox, Integrilin, study shows , TUESDAY, ... dialysis who undergo angioplasty are given blood thinners they should not ... are subject to a higher rate of bleeding during their hospital ... according to a report in the Dec. 9 issue of the ...
... the drug prevents flu complications such as pneumonia ... exists that the widely used influenza drug Tamiflu prevents ... come down with the flu, a new review contends. ... against flu-related complications have influenced governments worldwide to stockpile ...
... , NEW ... new market research report is available in its ... Cardiology 2009 (15 Countries) , ... for interventional cardiology was valued at over Euro1.5 ...
Cached Medicine News:Health News:Procter & Gamble Announces Appointment of Director 2Health News:New study finds low rate of injuries at overnight summer camp 2Health News:Beating Heart Differs by Gender, Age: Study 2Health News:Many Dialysis Patients Get Wrong Blood Thinners for Angioplasty 2Health News:Many Dialysis Patients Get Wrong Blood Thinners for Angioplasty 3Health News:Review Questions Tamiflu's Effectiveness 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21
The EZY Close post op shoe's flap-on-flap closure provides a secure fit and can accommodate even the bulkiest of dressing. Perfect for older patients with limited hand dexterity....
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
... who experience severe plantar fasciitis pain, the ... fibrous tissue that can occur after rest ... in the morning. The continuous tension and ... plantar fasciitis and helps stretch the Achilles ...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Medicine Products: